



QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO : Meghalayan Medical Drugs And Serv New colony shillong, DHS, laitumkhr director,NHM, Shillong, East Khasi Hi Shillong MFG. LICENCE No :			ah, Office of the mission	REPORT N ISSUE DAT CUSTOME DATE PAGE NO	E : R REFERENCE : :	EFRAC/2023/DRG/RG/0 22/11/2023 TRF 17/11/2023 1 of 3	3641		
			SAN	IPLE DETAILS	5				
<u>SAMP</u>	LE REGISTRATION	DETAIL	<u>S</u>		\sim	\mathbf{O}^{\prime}			
Sample Name		: Tab	b Albendazole 400mg Sample Quantity Received : 60.00 T Sample Registration Date : 17/11/ Sample Submitted/Drawn by : Client Batch Size : N/A						
Sample Receipt Date Registration No Name of Manufacturer Batch No.		: EFR/ : N/A	Date of Expiry : Mar-2026 EFRAC/2023/DRG/RG/03641 V/A MMDSL QC-0018						
Date o	f Mfg.	: Oct-	2023						
SAMPLE ANALYSIS DETAILS Analysis Starting Date			/11/2023	Analys	Analysis Completion Date : 20/11/2023				
	1			EST RESULT		1			
SL No.	TEST PARAMETER		TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS		
1	Description		Indian Pharmacopoeia 2022	-	_	Orange colour biconvex oval shaped uncoated tablet having red specs on whole body , one side plain and other side breakline chewable tablet.	Orange colour biconvex oval shaped uncoated tablet having red specs on whole body , one side plainand other sidebreakline chewable tablet.		









QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO : Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, laitumkhrah, Office of the mission director,NHM, Shillong, East Khasi Hills Meghalaya, 793003 Shillong, CP 3003 MFG. LICENCE NO :			REPORT N ISSUE DAT CUSTOME DATE PAGE NO	IE : IR REFERENCE : :	EFRAC/2023/DRG/RG/C 22/11/2023 TRF 17/11/2023 2 of 3	3641	
TEST RESULT							
SL No.	TEST PARAMETER	TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS	
2	Identification A	Indian Pharmacopoeia 2022	5		The principal spot in the chromatogram obtained with the test solution should correspond to that in the chromatogram obtained with the reference solution.	The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.	
3	Identification B	Indian Pharmacopoeia 2022	-	—	Should Comply	Complies	
4	Disintegration test	Indian Pharmacopoeia 2022	-	Min./Sec.	NMT 15 Mins	Min : 04 Min 26 Sec , Max : 05 Min 05 Sec	
5	Dissolution	Indian Pharmacopoeia 2022	400 mg/Tab	% of L.C.	NLT 85.0	Avg : 96.16 , Min : 95.74 , Max : 96.30	
6	Uniformity of the weight	Indian Pharmacopoeia 2022	-	%	(±)5.0	Avg wt : 872.25 mg , (-) Dev : 0.65, (+) Dev : 0.80	
7	Assay	Indian Pharmacopoeia 2022	400 mg/Tab	% of L.C.	370.0 - 430.0 mg/Tab i.e. 92.5 - 107.5	392.08 mg/Tab i.e. 98.02	

In the opinion of the undersigned, the Sample referred to above <u>is of Standard Quality</u> / <u>is not of Standard Quality</u> as defined in the Act or the Rules madethere under for the reasons given below:









QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO : Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, laitumkhrah, Office of the mission director,NHM, Shillong, East Khasi Hills Meghalaya, 793003	REPORT NO ISSUE DATE CUSTOMER REFERENCE DATE	
Shillong 293003	DATE	: 17/11/2023
NMFG. LICENCE NO :	PAGE NO	: 3 of 3

/11/2023

UOM : Unit of Measurement

:

REMARKS : The sample is tested as per test procedure shared by client and Opinion on Quality is drawn against the result obtained for tested parameter only.

FLECTK

Note

-END OF THE TEST REPORT-



